947179-06-8

Basic information

• Product Name: 4-(4-Fluoro-phenyl)-2-methyl-pyridine 1-oxide
• Synonyms: 4-(4-Fluoro-phenyl)-2-methyl-pyridine 1-oxide
• CAS NO: 947179-06-8
• Molecular Weight: 203.216
• Mol File: 947179-06-8.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 4-(4-Fluoro-phenyl)-2-methyl-pyridine 1-oxide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-Fluoro-phenyl)-2-methyl-pyridine 1-oxide(947179-06-8)
• EPA Substance Registry System: 4-(4-Fluoro-phenyl)-2-methyl-pyridine 1-oxide(947179-06-8)

Safety Data

• Hazardous Substances Data: 947179-06-8(Hazardous Substances Data)

Upstream product

• 22282-99-1 4-bromo-2-methylpyridine 
• 1765-93-1 4-fluoroboronic acid 
• 844818-54-8 4-(4-Fluoro-phenyl)-2-methyl-pyridine 

Downstream Products

• 791571-33-0 2-chloromethyl-4-(4-fluoro-phenyl)pyridine 
• 742682-91-3 C₁₂H₁₀FNO 
• 947179-07-9 4-(4-Fluoro-phenyl)-6-methyl-pyridine-2-carbonitrile 

Relevant articles and documents

Inhibition of 1-deoxy-d-xylulose-5-phosphate reductoisomerase by lipophilic phosphonates: SAR, QSAR, and crystallographic studies

1-Deoxy-d-xylulose-5-phosphate reductoisomerase (DXR) is a novel target for developing new antibacterial (including antituberculosis) and antimalaria drugs. Forty-one lipophilic phosphonates, representing a new class of DXR inhibitors, were synthesized, among which 5-phenylpyridin-2-ylmethylphosphonic acid possesses the most activity against E. coli DXR (EcDXR) with a K i of 420 nM. Structure-activity relationships (SAR) are discussed, which can be rationalized using our EcDXR:inhibitor structures, and a predictive quantitative SAR (QSAR) model is also developed. Since inhibition studies of DXR from Mycobacterium tuberculosis (MtDXR) have not been performed well, 48 EcDXR inhibitors with a broad chemical diversity were found, however, to generally exhibit considerably reduced activity against MtDXR. The crystal structure of a MtDXR:inhibitor complex reveals the flexible loop containing the residues 198-208 has no strong interactions with the 3,4-dichlorophenyl group of the inhibitor, representing a structural basis for the reduced activity. Overall, these results provide implications in the future design and development of potent DXR inhibitors.